





EDITORIAL PULMONARY INFECTIONS



Pandemic trials: evidence-based medicine on steroids

James D. Chalmers

Affiliation: Division of Molecular and Clinical Medicine, Ninewells Hospital, Dundee, UK.

Correspondence: James D. Chalmers, Division of Molecular and Clinical Medicine, Ninewells Hospital, Dundee, DD1 9SY, UK. E-mail: jchalmers@dundee.ac.uk

@ERSpublications

Small trials have been largely overlooked in the early part of the COVID-19 pandemic in favour of "mega-trials". As new therapies are urgently needed, phase 2 "proof of concept" studies are crucial as we move into a new phase of pandemic research. https://bit.ly/300K9kl

Cite this article as: Chalmers JD. Pandemic trials: evidence-based medicine on steroids. *Eur Respir J* 2020; 56: 2004116 [https://doi.org/10.1183/13993003.04116-2020].

This single-page version can be shared freely online.

Research is the only exit strategy from current coronavirus disease 2019 (COVID-19) restrictions. The second wave of COVID-19 infections currently affecting most of Europe emphasises that COVID-19, the disease caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is likely to require strict control measures impacting on the daily life of most citizens until either a highly effective approach to treatment or effective vaccines are in widespread use [1–3].

Copyright ©ERS 2020. This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.